Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F. Garrelfs, John C. Lieske, John M. Gansner et al.|New England Journal of Medicine|2021Cited by 505
A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3Cristina Martín-Higueras, Bernd Höppe, Sander F. Garrelfs et al.|Kidney International|2021Cited by 55
Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) RegistryElisabeth L. Metry, Jaap W. Groothoff, Sander F. Garrelfs et al.|Kidney International Reports|2021Cited by 36
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A. Hulton, John C. Lieske, Jaap W. Groothoff et al.|Kidney International Reports|2021Cited by 32
Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria ConsortiumElisabeth L. Metry, Hessel Peters‐Sengers, Sander F. Garrelfs et al.|Kidney International Reports|2023Cited by 29